VectorY CEO Sander van Deventer (L) and Forbion partner Wouter Joustra
November 13, 2023 09:30 AM EST
Financing
Startups

Neu­rode­gen­er­a­tive dis­ease-fo­cused Vec­to­rY nabs $138M to bring ALS vec­tor­ized an­ti­body to clin­ic

Katherine Lewin

News Reporter

Seed­ed by Eu­ro­pean VC firm For­bion in 2021, vec­tor­ized an­ti­body start­up Vec­to­rY has an­oth­er $138 mil­lion to work with in a Se­ries A co-led once …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times